Our History
Since 1999, our cell engineering expertise has helped to launch pioneering cell and gene therapy innovations
We are celebrating our 25-year anniversary as a pioneer in cell-engineering technologies. Since 1999, MaxCyte has consistently driven innovation in the biopharmaceutical industry. Over the years, we have developed cutting-edge technologies that became essential in the discovery, development, and commercialization of next-generation cell therapeutics.
Our journey is marked by a series of strategic partnerships and technological advancements that solidified our position as a leader in cell engineering. Our Flow Electroporation technology and ExPERT platform are advancing cell-based research and therapies, supporting biotech companies and researchers to develop groundbreaking treatments.
As we look to the future, we remain committed to pushing the boundaries of cell engineering, continuing our legacy of innovation and excellence to enable the next generation of cell-based therapies.
A history of innovation driving cell-engineering-based therapeutics
1999
MaxCyte is founded
Doug Doerfler and doctors Joseph Fratantoni and John Holaday start MaxCyte to commercialize our electroporation technology.
2000
The MaxCyte GT is launched
We launch our first electroporation instrument, the MaxCyte GT Scalable Transfection System, to overcome transfection challenges and enable cell therapy development and commercialization.
2002
FDA master file submitted
The first iteration of our United States Food and Drug Administration (FDA) master file, which customers can reference in their regulatory filings, is submitted.
2003
First licensing agreement signed
Our electroporation technology is licensed to companies developing human cell therapies.
2003
The MaxCyte STx is launched
We launch our instrument focused on cell-based assays and protein production—the MaxCyte STx Scalable Transfection System.
2014
Our second generation instruments are launched
The second generation of electroporators, known as "Gen 2," are launched with enhanced usability and a focus on regulatory compliance. These instruments are suitable for clinical applications and engineering a greater number of cells at one time.
2016
MaxCyte is listed on the London Stock Exchange
Our listing on AIM makes MaxCyte a publicly traded company with the ability to raise funding and expand internationally.
2019
The ExPERT platform is launched
We introduce the ExPERT ATx, ExPERT STx and ExPERT GTx instruments that allow customers to maintain their cell engineering workflows while scaling as needed on their path to a commercially available therapeutic.
2021
MaxCyte is listed on NASDAQ
MaxCyte's listing on NASDAQ supports our long-term growth and continued innovation after years of diligent efforts.
2022
The VLx system is launched
We continue to advance our cell-engineering capabilities with the launch of the ExPERT VLx instrument that is capable of transfecting 200 billion cells in less than 30 minutes.
2023
First approved therapy enabled by MaxCyte's technology
We are thrilled to support CRISPR Therapeutics and Vertex Pharmaceuticals in celebrating the FDA approval of their MaxCyte-enabled CRISPR/Cas9 gene-edited cell therapy, CASGEVY™, for the treatment of sickle cell disease and beta thalassemia.
